SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

LUPIN

BSE: 500257 22 May 2025
Healthcare
₹ 1968.45
Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

LUPIN - Share Price & Details

Market Cap
₹89,588
High /Low
2,403 / 1,493
Stock P/E
27.3
Book Value
₹377.0
Dividend Yield
0.4
ROCE
21.5
ROE
₹20.8
Face Value
2.0
PEG Ratio
0.49
EVEBITDA
₹16.8
Debt
5,448
CMP / FCF
59.5
Debt to equity
₹0.32
NP Ann
3,306
High price all time
2,403
Piotroski score
₹6.0
Graham Number
781.0
No. Eq. Shares
45.7
Net CF
₹560
Net profit
3,306
Price to book value
5.18
Interest Coverage
₹14.6
Low price all time
52.5
Industry PE
32.1
Reserves
₹17,112
Free Cash Flow
₹1,347

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic0.700.190.61NA4.1732.1
Triochem Products Ltd.,4.590.88NA3.600
LUPIN LTD.45344.612913.544856.728.2189,58827.3
AUROBINDO PHARMA LTD.29,708.904,720.5029,166.308.136927319.4
ABBOTT INDIA LTD.16,860.303,607.8016,142.80169.786562046.4

Peer Comparison Chart


About LUPIN

Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Lupin partners Honeywell for eco-friendly inhalers

(21 May 2025)
#New Delhi. Pharma...
Read more →

Lupin Ltd. Faces Continued Stock Decline Amid Broader Market Weakness

(20 May 2025)
Lupin Ltd. has faced a significant decline, marking its fourth consecutive day of losses. The stock is trading below all major moving...
Read more →

Lupin partners with Honeywell for usage of propellant for inhalers

(20 May 2025)
Lupin Ltd partners with Honeywell to incorporate 'Solstice Air' propellant in next-generation inhalers for asthma and COPD, aiming to reduce...
Read more →

Lupin collaborates with Honeywell, plans for HFO technology in Inhalers

(20 May 2025)
Lupin announced its plan to use Honeywell's Solstice Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the...
Read more →

Lupin to boost complex generics in US, EU; eyes chronic growth in India

(20 May 2025)
Lupin aims to grow complex generics revenue share to 62% by FY30 in the US and EU, while expanding its chronic portfolio in India and...
Read more →

The Silent Killer Meets Its Match: Digital Therapeutics In Hypertension Management

(20 May 2025)
Every morning, Mr. Sharma, a 62-year-old retired teacher from Pune, sits at his dining table with a cup of tea and his trusted blood...
Read more →